CSIMarket Company Name, Ticker, Customers, else..


Puma Biotechnology Inc   (NASDAQ: PBYI)
Other Ticker:  
 

Puma Biotechnology Inc

PBYI's Fundamental analysis



Looking into Puma Biotechnology Inc growth rates, revenue grew by 47.6 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 1836

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.75 %

Puma Biotechnology Inc 's net income grew by 855.64 % in III. Quarter 2024 year on year, above company average,

• More on PBYI's Growth


Puma Biotechnology Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Puma Biotechnology Inc PEG ratio is at -0.01 Company is currently trading with Price to Cash flow multiple of 33.87 in trailing twelve-month period.
Company
9.06
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.67.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.24.


• More on PBYI's Valuation
 
 Total Debt (Millions $) 78
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 2,230,461
 Net Income/Employee (TTM) $ 164,402
 Receivable Turnover (TTM) 6.68
 Tangible Book Value (Per Share $) 0.36

Puma Biotechnology Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Puma Biotechnology Inc PEG ratio is at -0.01 Company is currently trading with Price to Cash flow multiple of 33.87 in trailing twelve-month period.
Company
9.06
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.67.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.24.

Puma Biotechnology Inc Price to Book Ratio is at 2.13 lower than Industry Avg. of 86. and higher than S&P 500 Avg. of 0.01

• More on PBYI's Valuation

•  Market Capitalization (Millions $) 151
•  Shares Outstanding (Millions) 49
•  Employees 102
•  Revenues (TTM) (Millions $) 228
•  Net Income (TTM) (Millions $) 17
•  Cash Flow (TTM) (Millions $) 4
•  Capital Exp. (TTM) (Millions $) 0
•  Total Debt (Millions $) 78
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 2,230,461
•  Net Income/Employee(TTM) $ 164,402
•  Receivable Turnover Ratio (TTM) 6.68
•  Tangible Book Value (Per Share $) 0.36

•  Market Capitalization (Millions $) 151
•  Shares Outstanding (Millions) 49
•  Employees 102
•  Revenues (TTM) (Millions $) 228
•  Net Income (TTM) (Millions $) 17
•  Cash Flow (TTM) (Millions $) 4
•  Capital Exp. (TTM) (Millions $) 0


    PBYI's Profitability Comparisons
Puma Biotechnology Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 27.41 %.

Puma Biotechnology Inc net profit margin of 25.23 % is currently ranking no. 21 in Major Pharmaceutical Preparations industry, ranking no. 40 in Healthcare sector and number 512 in S&P 500.


Profitability by Segment
Total 25.23 %



  Ratio
•   Capital Ratio (MRQ) 1.42
•  Total Debt to Equity (MRQ) 1.1
•  Tangible Leverage Ratio (MRQ) 8.54
•  Asset Turnover Ratio (TTM) 1.08
•  Inventory Turnover Ratio (TTM) 10.41



Puma Biotechnology Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 27.41 %.

Puma Biotechnology Inc net profit margin of 25.23 % is currently ranking no. 21 in Major Pharmaceutical Preparations industry, ranking no. 40 in Healthcare sector and number 512 in S&P 500.

• More on PBYI's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com